Dr. Tripathy Discusses Neratinib in HER2+ Breast Cancer

Debu Tripathy, MD
Published: Monday, Dec 11, 2017



Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neratinib (Nerlynx) for the treatment of patients with HER2-positive breast cancer.

Neratinib was approved by the FDA in July 2017 for the extended adjuvant treatment of patients with early stage, HER2-positive breast cancer following postoperative trastuzumab (Herceptin).

Tripathy says that this drug initially showed a small advantage in this population, but with longer follow-up the improvement is growing, with a 5% difference in recurrence rate.
 


Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neratinib (Nerlynx) for the treatment of patients with HER2-positive breast cancer.

Neratinib was approved by the FDA in July 2017 for the extended adjuvant treatment of patients with early stage, HER2-positive breast cancer following postoperative trastuzumab (Herceptin).

Tripathy says that this drug initially showed a small advantage in this population, but with longer follow-up the improvement is growing, with a 5% difference in recurrence rate.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
14th Annual School of Breast Oncology® OnlineFeb 10, 201825
Publication Bottom Border
Border Publication
x